Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
60 participants
INTERVENTIONAL
2022-10-18
2024-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does metformin have beneficial effect on epileptic patients?
* How metformin can affect epileptic patient's health?
Participants will be divided into 2 groups (control group and treatment group)
* Control group will receive standard treatment (levetiracetam \&/or sodium valproate).
* Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group (+ve control)
levetiracetam \&/or sodium valproate
Levetiracetam &/or sodium valproate
levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
Treatment group
metformin + (levetiracetam \&/or sodium valproate)
Levetiracetam &/or sodium valproate
levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
Metformin
metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levetiracetam &/or sodium valproate
levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
Metformin
metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Obese and overweight patients with body mass index (BMI) ≥ 25.
* Diabetic \& non diabetic patients.
Exclusion Criteria
* Patients having acute or chronic disease which may cause tissue hypoxia and increase the risk of lactic acidosis (e.g. cardiac/respiratory failure, recent myocardial infarction).
* Patients who are already taking metformin.
* Cancer patients.
* Pregnant or lactating women.
* Patients with known hypersensitivity to the drug.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omnia Ashraf Abd El Aziz Ahmed
Teacher Assisstant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Omnia Ashraf Abd El Aziz Ahmed Kotb
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0107353
Identifier Type: -
Identifier Source: org_study_id